Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. to Market Generic Depakote(R) Delayed Release Tablets
Date:7/30/2008

DETROIT, July 30 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (Amex: CPD) announced today, that it has launched divalproex sodium delayed release tablets on behalf of Sun Pharmaceutical Industries Ltd. (Sun Pharma). Sun Pharma recently received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for generic Depakote(R) delayed release tablets.

Divalproex sodium delayed release tablets are indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures, as sole and adjunct therapy for patients with simple and complex absence seizures, for the treatment of the manic episodes associated with bipolar disorders, as well as for prophylaxis of migraine headaches. These generic versions of divalproex sodium delayed release 125 mg, 250 mg, and 500 mg (valproic acid activity) tablets are bioequivalent to Depakote(R) delayed release tablets distributed by Abbott Laboratories. According to IMS Data, Depakote(R) had US. sales of approximately $750 million for the 12-month period ended March 2008.

Depakote(R) is a registered trademark of Abbott Laboratories.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission and include, but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or cheaper products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward- looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.


'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Elavil(R)
2. Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008
3. Caraco Pharmaceutical Laboratories, Ltd. to Announce Fourth Quarter and Fiscal Year 2008 Results on May 29, 2008
4. Caraco Pharmaceutical Laboratories Ltd. Wins Summary Judgment on Generic Ultracet(R)
5. Caraco Pharmaceutical Laboratories Ltd. To Market Generic Ethyol(R)
6. Caraco Pharmaceutical Laboratories Ltd. to Market Generic Protonix(R)
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Childrens Zyrtec(R) Chewable Tablets for Allergy Relief and Childrens Zyrtec(R) Chewable Tablets for Hives Relief
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Norvasc(R)
11. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lexapro(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Diego, CA (PRWEB) , ... December 05, 2016 , ... ... seen and heard the dangers and downsides of patients who do not do their ... The field of cosmetic dermatology is in the midst of a renaissance and every ...
(Date:12/4/2016)... , ... December 02, 2016 , ... ... give patients better access to nutraceuticals and help doctors more efficiently manage their ... portal and practice management software platform for Integrative and Functional Medicine. , ...
(Date:12/4/2016)... TX (PRWEB) , ... December 03, 2016 , ... ... the “Fastest growing Entrepreneurial Company in the Dallas area” Tuesday evening at the ... Omni Dallas Hotel, presented by SMU's Cox School’s Caruth Institute for Entrepreneurship. Dallas ...
(Date:12/2/2016)... California (PRWEB) , ... December 02, 2016 , ... Halfway ... Dental Medicine has provided preventative dental services to more than 15,900 children 5 years ... First 5 LA pledged $38 million over a span of five years to Western ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... Area in Alabama are expected to attend the UNCF Dothan-Wiregrass Mayor’s Luncheon Dec. ... scholarship funds for area students and operating support to UNCF-member institutions, including Miles ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... HOUSTON , Dec. 3, 2016   Pairnomix, LLC, ... Precision Medicine Alliance (PEPMA) recognized by the White House, today ... individualized approach to the identification of candidate therapies for a ... SCN8A gene were presented at the 70 th ... in Houston, TX , December 2-6, 2016.  ...
(Date:12/4/2016)... , Dec. 3, 2016  Results from the ... SelG1), an anti-P-selectin antibody, reduced the median annual rate ... to placebo (1.63 vs 2.98, p=0.010) in patients with ... that the data are being featured in the official ... of Hematology (ASH) Annual Meeting and presented during the ...
(Date:12/4/2016)... EAST HANOVER, N.J. , Dec. 3, 2016 ... evaluating efficacy and safety of CTL019, an investigational ... in relapsed/refractory (r/r) pediatric and young adult patients ... presented today during an oral session at the ... (Abstract #221, December 3, 4:00-5:30 p.m.). The global ...
Breaking Medicine Technology: